Dr. Tolaney on Pembrolizumab Plus Eribulin in TNBC

Name: Dr. Tolaney on Pembrolizumab Plus Eribulin in TNBC
Uploaded: 2016-12-10T05:15:07.000Z
Description: Sara M. Tolaney, MD, MPH, associate director, Clinical Research, Breast Oncology, Susan F. Smith Center for Women's Cancers, senior physician, instructor in Medicine, Harvard Medical School, discusses a phase Ib/II trial exploring eribulin mesylate (Halaven) in combination with pembrolizumab (Keytruda) in patients with metastatic triple-negative breast cancer (TNBC).

December 10, 2016

Sara M. Tolaney, MD, MPH

Video

Conference|San Antonio Breast Cancer Symposium

Sara M. Tolaney, MD, MPH, associate director, Clinical Research, Breast Oncology, Susan F. Smith Center for Women's Cancers, senior physician, instructor in Medicine, Harvard Medical School, discusses a phase Ib/II trial exploring eribulin mesylate (Halaven) in combination with pembrolizumab (Keytruda) in patients with metastatic triple-negative breast cancer (TNBC).

<<<